Hospital Kloster Grafschaft, Department of Respiratory and Critical Care Medicine, Schmallenberg, Germany.
J Aerosol Med Pulm Drug Deliv. 2011 Dec;24(6):285-92. doi: 10.1089/jamp.2011.0883. Epub 2011 Aug 26.
Inhaled bronchodilators are frequently used in patients with chronic obstructive pulmonary disease (COPD). However, there has been no efficient way to administer the long-acting anticholinergic tiotropium to mechanically ventilated patients. The aim of this in vitro study was to compare the fine particle dose (FPD) output of a specifically designed adapter with other accessory devices for the delivery of bronchodilators using the Respimat® (RMT) inhaler by simulating the specific inhalation flow profiles of patients with COPD.
Using characteristic flow profiles from COPD patients being weaned off mechanical ventilation, an in vitro study was performed analyzing the FPD achieved with different accessory devices (connectors, spacers, AeroTrachPlus valved holding chamber), which can be used to deliver drugs from pressurized metered dose inhalers (pMDI) and RMT inhalers to artificial airways. Fenoterol pMDI, tiotropium RMT, and a fixed-dose combination of salbutamol and ipratropium delivered by pMDI or RMT, were used as bronchodilators. Aerosols were collected by a next-generation impactor.
The RMT inhaler, combined with a new in-line adapter, was superior to other inhaler device connector or spacer combinations in FPD delivery during simulated mechanical ventilation (p<0.01). The outcome with the RMT inhaler/RMT adapter combination during simulation of mechanical ventilation was comparable to the measurements with the RMT/AeroTrachPlus valved holding chamber during simulation of spontaneous breathing. The delivery rates of the RMT adapter were not significantly affected by the administered bronchodilators or by the type of artificial airway (endotracheal or tracheostomy tube) employed.
The RMT inhaler combined with the prototype in-line adapter was better than the other accessory device combinations in fine particle deposition of inhaled bronchodilators during mechanical ventilation. Further research is required to determine the clinical relevance of these in vitro findings.
在慢性阻塞性肺疾病(COPD)患者中,经常使用吸入性支气管扩张剂。然而,对于机械通气的患者,还没有有效的方法来施用长效抗胆碱能药物噻托溴铵。本体外研究的目的是通过模拟 COPD 患者的特定吸入流量曲线,比较专门设计的适配器与其他附件设备在使用 Respimat®(RMT)吸入器输送支气管扩张剂时的微细颗粒剂量(FPD)输出。
使用从机械通气脱机的 COPD 患者的特征性流量曲线,进行了一项体外研究,分析了不同附件设备(接头、间隔器、AeroTrachPlus 带阀保持室)实现的 FPD,这些设备可用于将药物从压力定量吸入器(pMDI)和 RMT 吸入器输送至人工气道。使用福莫特罗 pMDI、噻托溴铵 RMT 以及 pMDI 或 RMT 输送的沙丁胺醇和异丙托溴铵的固定剂量组合作为支气管扩张剂。气溶胶通过下一代撞击器收集。
在模拟机械通气期间,与其他吸入器设备接头或间隔器组合相比,RMT 吸入器与新型在线适配器联合使用在 FPD 输送方面具有优势(p<0.01)。在模拟机械通气期间,RMT 吸入器/RMT 适配器组合的结果与在模拟自主呼吸期间,RMT/AeroTrachPlus 带阀保持室的测量结果相当。RMT 适配器的输送速率不受所施用的支气管扩张剂或所使用的人工气道(气管内或气管造口管)类型的影响。
在机械通气期间,与其他附件设备组合相比,RMT 吸入器与原型在线适配器联合使用更有利于吸入性支气管扩张剂的微细颗粒沉积。需要进一步的研究来确定这些体外发现的临床相关性。